A conventional meta-analysis conducted on the treatment effect measures (Hazard ratio) of Lev administration on OS supports a positive effect of LEV administration in patients with unmethylated MGMT-promoters high-grade gliomas (IDH mutant or IDH wild-type) [14]. The gene discussed is IDH1; the disease is glioma.